As the pharmaceutical industry pushes towards full DSCSA compliance this November, stakeholders and the FDA have made efforts to streamline and improve processes to ensure the security and integrity of the drug supply chain.
Envision Pharma Group (Envision) announced today the appointment of Bill Shirey as President of Life Science Commercialization. Overseeing the Two Labs and Riparian brands, Bill will focus on enhancing Envision’s commercialization and compliance solutions, delivering customized strategies that help bring pharmaceutical products to market and maintain compliance across the product life cycle through industry expertise, integration, and strategic implementation.
This year’s Asembia Summit was not just an event; it was a powerhouse of innovation and strategic conversations that set new benchmarks for patient care within the pharmaceutical industry. Asembia served as the nexus for fostering connections and driving transformative ideas. Below, we dive into the key insights and takeaways that are steering our industry toward a more innovative and efficient future, spotlighting the groundbreaking work and collaborations that are defining the path forward.
The medical device industry is growing, and we’re seeing the impact at Two Labs as more and more clients are asking us for support in launching their new medical device products.
Pharmaceutical and medical device manufacturers launching their first product in the US face several complex challenges while preparing for the required collection and reporting of transfers of value provided to healthcare providers (HCPs) and healthcare organisations (HCOs). The many unique federal and state legal requirements, coupled with steep penalties for inaccurate, incomplete, or late reporting, underscore the critical need for a strategic, well-organised transparency reporting programme.
